Project Grant R41AI170290
Award Date
5/6/22
Completion Date
4/30/23
Dollars Obligated
$578K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $299,921 to Ubiquitx Inc., a New York-based biotechnology company, to develop a therapeutic platform for upregulating antigen presentation to enhance immune surveillance of diseased cells. The award supports the development and characterization of Ubiquitinase Chimeric Ligands for Induced Proximity (UbiClips)...
The National Institute of Allergy and Infectious Diseases (NIAID), through the Allergy and Infectious Diseases Research program (CFDA 93.855), has awarded a $300,000 Project Grant to Biotherapeutics, Inc., a biotech company located in Blacksburg, Virginia. The grant aims to accelerate the development of Biotherapeutics' novel, oral, first-in-class immunoregulatory therapeutic for the treatment of Clostridioides difficile infection (CDI). The specific objectives of this SBIR Phase I grant are to:...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded Partillion Bioscience Corp a $1,000,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports the company's development of advanced workflows utilizing their specialized "nanovial" hydrogel microparticle technology to enable ultra high-throughput screening and functional assessment of antibodies derived from single B cells and antibody-secreting cells. The...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $891,678 Project Grant (R01AI182439) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute in La Jolla, CA. The project, titled "Chemoproteomic Discovery and Functional Analysis Microbiota Bile Acid-Protein Targets in Host Immunity", aims to identify and characterize how metabolites from the intestinal microbiota, specifically bile acids, modulate host immune...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $288,360 Project Grant to Biological Mimetics, Inc. to develop a novel vaccine candidate against multi-drug resistant Acinetobacter baumannii (MDR-AB). The project aims to (1) identify and characterize key immunogenic components of MDR-AB that can elicit protective immunity, (2) develop a prototype vaccine formulation, and (3) conduct...
This $600,000 project grant from the National Institute of Allergy and Infectious Diseases will support General Nanotherapeutics LLC's development of nanoimmunotherapy for chronic immune-mediated diseases. The company will leverage nanoparticles to target and expand immunoregulatory cells ex vivo and assess their ability to suppress effector immune responses and induce remission in vivo, including in a lupus model. This proof-of-concept work aligns with the Allergy and Infectious Diseases...
This Project Grant award for $244,440.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the mechanisms by which inflammatory Ly6C+ monocytes home to and form stable clusters at sites of microbial pathogen infections. The goal is to better understand how these immune cells deliver powerful effector functions to help clear pathogens. The research will...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, has awarded a $300,156 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Intact Genomics Inc., a minority-owned small business. The funding will support research to identify new antifungal compounds with novel mechanisms of action from filamentous fungi. The key objectives are to demonstrate the use of Aspergillus nidulans as a...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to uncover the role of miR-29a in regulating the epigenetic profile and differentiation of exhausted CD8 T cells. The $1,684,130 award aims to elucidate how miR-29a targets the TET2 enzyme to alter DNA methylation, and how this miR-29a-TET2 axis synergizes with checkpoint inhibitor therapy to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant totaling $392,634 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Wisconsin-Madison on May 13, 2025. The funding supports the development of a novel broad-spectrum nanoimmunotherapeutic approach for combating multidrug-resistant (MDR) bacterial infections, particularly those caused by the ESKAPE pathogens. The project aims to design, fabricate, and optimize a...